L
Leszek Szczepanski
Publications - 8
Citations - 5247
Leszek Szczepanski is an academic researcher. The author has contributed to research in topics: Rheumatoid arthritis & Rituximab. The author has an hindex of 8, co-authored 8 publications receiving 5082 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
Jonathan C. W. Edwards,Leszek Szczepanski,Jacek Szechiński,Anna Filipowicz-Sosnowska,Paul Emery,D. Close,Randall M Stevens,T. Shaw +7 more
TL;DR: In patients with active rheumatoid arthritis despite methotrexate treatment, a single course of two infusions of rituximab, alone or in combination with either cyclophosphamide or continued methotRexate, provided significant improvement in disease symptoms at both weeks 24 and 48.
Journal ArticleDOI
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Paul Emery,Roy Fleischmann,Anna Filipowicz-Sosnowska,Joy Schechtman,Leszek Szczepanski,Arthur Kavanaugh,Artur Racewicz,Ronald F van Vollenhoven,Nicole F. Li,Sunil Agarwal,E. W. Hessey,T. Shaw +11 more
TL;DR: Both rituximab doses were effective and well tolerated when added to MTX therapy in patients with active rheumatoid arthritis, although intravenous glucocorticoid premedication improved tolerability during the first ritUXimab infusion.
Journal ArticleDOI
Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs
Christopher J. Hawkey,Jeffrey A. Karrasch,Leszek Szczepanski,Donald G. Walker,Alan N. Barkun,A J Swannell,Neville D. Yeomans +6 more
TL;DR: The efficacy of omeprazole and misoprostol in healing and preventing ulcers associated with NSAIDs and the presence of fewer than five erosions at each site and not more than mild dyspepsia was compared.
Journal ArticleDOI
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
Paul Emery,A. Deodhar,William F. C. Rigby,John D. Isaacs,B. Combe,Artur Racewicz,Kevin Latinis,Carlos Abud-Mendoza,Leszek Szczepanski,R. A. Roschmann,A. Chen,Gillian Armstrong,Wendy Douglass,H. Tyrrell +13 more
TL;DR: Rituximab (at 2×500 mg and 2×1000 mg) plus MTX significantly improved clinical outcomes at week 24, which were further improved by week 48, and no significant differences in either clinical or safety outcomes were apparent between the rituxIMab doses.
Journal ArticleDOI
Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs
Christopher J. Hawkey,Jeffrey A. Karrasch,Leszek Szczepanski,Donald G. Walker,Alan N. Barkun,A J Swannell,Neville D. Yeomans +6 more
TL;DR: The overall rates of successful treatment of ulcers, erosions, and symptoms associated with NSAIDs were similar for the two doses of omeprazole and misoprostol.